Get started
Author

Gerado Rosati

Observed names: G Rosati, G. Rosati
Institution: Ospedale San Carlo
ORCID: 0000-0001-7004-6862
Observed ORCID: 0000-0001-7004-6862
OpenAlex ID: A5043970992
Ceravolo
2004 · M. Cantore, G. Fiorentini, et al. · Journal of Chemotherapy · 25
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.
2012 · Emilio Bajetta, Irene Floriani, et al. · Journal of Clinical Oncology · 15
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
2003 · M Cantore, G Fiorentini, et al. · PubMed · 12
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.
2012 · Emilio Bajetta, Irene Floriani, et al. · Journal of Clinical Oncology · 8
Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy
2005 · Drug Utilization Review Team in Oncology (DURTO), Fausto Roila, et al. · Tumori Journal · 5
ITACA-S (Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach) trial: comparison of a sequential treatment with irinotecan (cpt-11) + 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.
2012 · Emilio Bajetta, Irene Floriani, et al. · Tumori · 3
Multicenter phase II study of every-2 week gemcitabine and paclitaxel as first-line chemotherapy in patients with advanced urothelial tract cancer
2005 · F. Calabro, C. N. Sternberg, et al. · Journal of Clinical Oncology · 2
Phase II trial of paclitaxel (P) and cisplatin (COOP) in patients with advanced breast cancer refractory to anthracycline (A) therapy
1997 · F. Riccardi, G. Rosati, et al. · European Journal of Cancer · 1
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
2026 · D. Ciardiello, L. Boscolo Bielo, et al. · ESMO Gastrointestinal Oncology
PDF
156P Genomic and transcriptomic profiling of metastatic colorectal (mCRC) patients (pts) receiving FOLFOXIRI/bevacizumab (bev) combined with nivolumab (niv) as first-line therapy in the NIVACOR trial
2025 · N. Normanno, A. Damato, et al. · Annals of Oncology
PDF
534P Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
2024 · A. Cordua, D. Basile, et al. · Annals of Oncology
PDF
109P Prognostic genomic signatures in RAS/BRAF mutant (mut) metastatic colorectal cancer (mCRC) patients (pts) from the phase II study of NIVolumab (niv) plus FOLFOXIRI/Bevacizumab (bev) in first-line therapy of Advanced COloRectal cancer (NIVACOR- GOIRC-03-2018)
2024 · N. Normanno, A. Damato, et al. · Annals of Oncology
2357 Prognostic factors in 709 advanced gastric cancer patients exposed to second-line therapy
2015 · C. Fontanella, V. Fanotto, et al. · European Journal of Cancer
A phase II study of irinotecan (CPT-11) alternated with a weekly schedule of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour infusion 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (MCRC)
2001 · G. Rosati, A. Tucci, et al. · European Journal of Cancer
Systemic treatment with granulocyte macrophage colony-stimulating factor (GM-CSF) of severe mucositis induced by 5-fluorouracil (5-FU) based chemotherapy
2001 · A. Rossi, G. Rosati, et al. · European Journal of Cancer
A phase II randomized study of cisplatin (CDDP), raltitrexed (TOM), levofolinic acid (LFA), and 5-fluorouracil (5-FU), or CDDP, methotrexate (MTX), LFA and 5-FU in locally advanced (LAD) or metastatic (M) head and neck cancer (HNC)
2001 · F. Caponigro, P. De Rosa, et al. · European Journal of Cancer
A phase II study of alternating cycles of CPT-11 and high-dose 48 hour infusion 5-FU in combination with leucovorin (HD-5-FU/LV) in no selective patients with metastatic colorectal cancer (MCRC)
1999 · G. Rosati, D. Bilancia, et al. · European Journal of Cancer
Works count: 17
Citation count: 71
H-index: 5
I10-index: 3
Year
Topic
Type